Ami Fadia
Stock Analyst at Needham
(4.31)
# 460
Out of 4,655 analysts
351
Total ratings
58.04%
Success rate
13.84%
Average return
Main Sectors:
Stocks Rated by Ami Fadia
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BPMC Blueprint Medicines | Reiterates: Buy | $135 | $88.69 | +52.22% | 24 | Nov 15, 2024 | |
| IMRX Immuneering | Reiterates: Buy | $15 | $1.80 | +733.33% | 10 | Nov 14, 2024 | |
| COGT Cogent Biosciences | Maintains: Buy | $16 → $15 | $8.90 | +68.54% | 18 | Nov 13, 2024 | |
| AXSM Axsome Therapeutics | Reiterates: Buy | $130 | $93.17 | +39.53% | 6 | Nov 13, 2024 | |
| NMRA Neumora Therapeutics | Reiterates: Buy | $23 | $10.84 | +112.18% | 5 | Nov 13, 2024 | |
| AVDL Avadel Pharmaceuticals | Reiterates: Buy | $22 | $10.91 | +101.65% | 31 | Nov 13, 2024 | |
| NBIX Neurocrine Biosciences | Reiterates: Hold | n/a | $117.44 | - | 10 | Nov 11, 2024 | |
| RVMD Revolution Medicines | Maintains: Buy | $61 → $68 | $55.13 | +23.34% | 18 | Nov 7, 2024 | |
| JAZZ Jazz Pharmaceuticals | Reiterates: Buy | $207 | $121.65 | +70.16% | 24 | Nov 7, 2024 | |
| ACAD ACADIA Pharmaceuticals | Reiterates: Buy | $28 | $16.77 | +66.96% | 6 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $151 | $71.76 | +110.42% | 7 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $85 | $46.58 | +82.48% | 21 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $38 | $21.79 | +74.39% | 15 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $270 | $159.99 | +68.76% | 35 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $33 | $13.31 | +147.93% | 17 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $100 | $83.42 | +19.88% | 25 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $52 | $33.22 | +56.56% | 29 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $5.10 | - | 17 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $16 | $0.50 | +3,100.00% | 2 | Feb 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $63 → $75 | $16.60 | +351.81% | 7 | Jan 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $15 → $23 | $1.37 | +1,542.34% | 4 | Oct 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $64 → $63 | $26.81 | +134.99% | 5 | Sep 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $12 → $5 | $3.46 | +44.51% | 2 | Jan 30, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Perform | n/a | $16.43 | - | 9 | Oct 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $1.19 | +1,748.74% | 4 | Jan 3, 2018 |
Blueprint Medicines
Nov 15, 2024
Reiterates: Buy
Price Target: $135
Current: $88.69
Upside: +52.22%
Immuneering
Nov 14, 2024
Reiterates: Buy
Price Target: $15
Current: $1.80
Upside: +733.33%
Cogent Biosciences
Nov 13, 2024
Maintains: Buy
Price Target: $16 → $15
Current: $8.90
Upside: +68.54%
Axsome Therapeutics
Nov 13, 2024
Reiterates: Buy
Price Target: $130
Current: $93.17
Upside: +39.53%
Neumora Therapeutics
Nov 13, 2024
Reiterates: Buy
Price Target: $23
Current: $10.84
Upside: +112.18%
Avadel Pharmaceuticals
Nov 13, 2024
Reiterates: Buy
Price Target: $22
Current: $10.91
Upside: +101.65%
Neurocrine Biosciences
Nov 11, 2024
Reiterates: Hold
Price Target: n/a
Current: $117.44
Upside: -
Revolution Medicines
Nov 7, 2024
Maintains: Buy
Price Target: $61 → $68
Current: $55.13
Upside: +23.34%
Jazz Pharmaceuticals
Nov 7, 2024
Reiterates: Buy
Price Target: $207
Current: $121.65
Upside: +70.16%
ACADIA Pharmaceuticals
Nov 7, 2024
Reiterates: Buy
Price Target: $28
Current: $16.77
Upside: +66.96%
Nov 7, 2024
Reiterates: Buy
Price Target: $151
Current: $71.76
Upside: +110.42%
Nov 1, 2024
Reiterates: Buy
Price Target: $85
Current: $46.58
Upside: +82.48%
Oct 31, 2024
Reiterates: Buy
Price Target: $38
Current: $21.79
Upside: +74.39%
Oct 31, 2024
Reiterates: Buy
Price Target: $270
Current: $159.99
Upside: +68.76%
Oct 31, 2024
Reiterates: Buy
Price Target: $33
Current: $13.31
Upside: +147.93%
Oct 31, 2024
Reiterates: Buy
Price Target: $100
Current: $83.42
Upside: +19.88%
Oct 30, 2024
Reiterates: Buy
Price Target: $52
Current: $33.22
Upside: +56.56%
Oct 30, 2024
Reiterates: Hold
Price Target: n/a
Current: $5.10
Upside: -
Feb 1, 2021
Maintains: Outperform
Price Target: $12 → $16
Current: $0.50
Upside: +3,100.00%
Jan 21, 2021
Downgrades: Market Perform
Price Target: $63 → $75
Current: $16.60
Upside: +351.81%
Oct 1, 2020
Maintains: Market Perform
Price Target: $15 → $23
Current: $1.37
Upside: +1,542.34%
Sep 17, 2020
Maintains: Outperform
Price Target: $64 → $63
Current: $26.81
Upside: +134.99%
Jan 30, 2019
Downgrades: Market Perform
Price Target: $12 → $5
Current: $3.46
Upside: +44.51%
Oct 1, 2018
Upgrades: Market Perform
Price Target: n/a
Current: $16.43
Upside: -
Jan 3, 2018
Initiates: Outperform
Price Target: $22
Current: $1.19
Upside: +1,748.74%